Goldman Sachs Maintains Neutral on Halozyme Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Graig Suvannavejh has maintained a Neutral rating on Halozyme Therapeutics (NASDAQ:HALO) but reduced the price target from $45 to $40.
January 18, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Halozyme Therapeutics and lowered the price target from $45 to $40, which may influence the stock's performance.
The reduction in price target by a prominent analyst like Goldman Sachs can lead to a negative perception among investors, potentially causing a short-term decline in the stock price of Halozyme Therapeutics.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100